• / Free eNewsletters & Magazine
  • / My Account
Home>Funds>Morgan Stanley Ins Muni Secs

Morgan Stanley Ins Muni Secs

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. QuintilesIMS Announces Launch of Secondary Public Offering, Repurchase of Common Stock and Increase in Share Buyback Authorization

    QuintilesIMS Announces Launch of Secondary Public Offering, Repurchase of Common Stock and Increase in Share Buyback Authorization

  2. Contract Research Outsourcing Report 2017 - Analysis By Drug Discovery, Preclinical Research & Clinical Research - Research and Markets

    Contract Research Outsourcing Report 2017 - Analysis By Drug Discovery, Preclinical Research & Clinical Research - Research and Markets

  3. Dr. Reddy's Laboratories Announces USFDA Approval for the Launch of Doxorubicin Hydrochloride Liposome Injection in the U.S. Market

    Dr. Reddy's Laboratories Announces USFDA Approval for the Launch of Doxorubicin Hydrochloride Liposome Injection in the U.S. Market

  4. VCLS Appoints Carole Jones, Director, Market Access

    VCLS Appoints Carole Jones, Director, Market Access

  5. The Collaborative Gene and Its Impact on Life Science Ecosystem Development: An Arizona Business Case

    The Collaborative Gene and Its Impact on Life Science Ecosystem Development: An Arizona Business Case

  6. Jacquet Metal Service: Q1 2017 Results

    Jacquet Metal Service: Q1 2017 Results

  7. Charles River Partners with OTAS to Improve Trading Efficiency and Transparency for Buy-Side Firms

    Charles River Partners with OTAS to Improve Trading Efficiency and Transparency for Buy-Side Firms

  8. Tel-Instrument Electronics Corp. Announces $2.8 Million Adverse Jury Verdict in Kansas Aeroflex Litigation

    Tel-Instrument Electronics Corp. Announces $2.8 Million Adverse Jury Verdict in Kansas Aeroflex Litigation

  9. Hudson Technologies Reports Revenues of $38.8 Million for First Quarter 2017; Diluted EPS of $0.13

    Hudson Technologies Reports Revenues of $38.8 Million for First Quarter 2017; Diluted EPS of $0.13

  10. BIO Statement on Blue Cross Blue Shield Prescription Drug Spending Report

    BIO Statement on Blue Cross Blue Shield Prescription Drug Spending Report

123

©2017 Morningstar Advisor. All right reserved.